Global Genitourinary System Treatment

Genitourinary System Treatment Comprehensive Study by Type (OTC, Rx Drugs), Application (Hospital, Clinics, Ambulatory Surgical Centers), Drugs (Hormonal Therapy, Impotence Agents, Uterine Relaxants, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Stimulants, Miscellaneous Genitourinary Tract Agents), Disease Type (Renal Failure, Pyelonephritis, Calculus of Kidney and Ureter, Cystitis, Cancer, Infertility, Endometriosis, Others) Players and Region - Global Market Outlook to 2029

Genitourinary System Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Genitourinary System Treatment
Genitourinary system are the organs of the reproductive system and the urinary system consist of two kidneys, two ureters, one urinary bladder, and one urethra as well as the prostate gland, testicles, and epididymis in men, and the uterus, fallopian tubes, ovaries, vagina, external genitalia, and perineum in women. The treatment of genitourinary injuries depends upon a number of factors including the severity, location and type of injury.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)


Analyst at AMA Research estimates that france Players will contribute the maximum growth to Global Genitourinary System Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc. (United KIngdom), Eli Lilly and Company (United States), Bayer AG (Germany), Merck KGaA (Germany), Abbott Laboratories (United States) and Merck & Co. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Agouron Pharmaceuticals Inc. (United States) and Bristol-Myers Squibb Co. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Genitourinary System Treatment market by Type (OTC and Rx Drugs), Application (Hospital, Clinics and Ambulatory Surgical Centers) and Region.



On the basis of geography, the market of Genitourinary System Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Hormonal Therapy will boost the Genitourinary System Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Type, the sub-segment i.e. Renal Failure will boost the Genitourinary System Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in the Healthcare Technology

Market Growth Drivers:
Increasing Prevalence of Genitourinary System Disorders and Rise in the Number of Hospitals and Clinics

Challenges:
Less Awareness among people in Developing Regions

Restraints:
Side Effects of the Drugs

Opportunities:
Growth in the Pharmaceutical Industry and Constant Improvements in the Healthcare Infrastructure

Market Leaders and their expansionary development strategies
In October , 2022 Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha’s adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN.
In Feb. 2023 Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.


Key Target Audience
Genitourinary System Treatment Providers, Research Professionals, Distributors and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • OTC
  • Rx Drugs
By Application
  • Hospital
  • Clinics
  • Ambulatory Surgical Centers
By Drugs
  • Hormonal Therapy
  • Impotence Agents
  • Uterine Relaxants
  • Urinary Antispasmodics
  • Urinary pH Modifiers
  • Uterine Stimulants
  • Miscellaneous Genitourinary Tract Agents

By Disease Type
  • Renal Failure
  • Pyelonephritis
  • Calculus of Kidney and Ureter
  • Cystitis
  • Cancer
  • Infertility
  • Endometriosis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Genitourinary System Disorders
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness among people in Developing Regions
    • 3.4. Market Trends
      • 3.4.1. Advancements in the Healthcare Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genitourinary System Treatment, by Type, Application, Drugs, Disease Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Genitourinary System Treatment (Value)
      • 5.2.1. Global Genitourinary System Treatment by: Type (Value)
        • 5.2.1.1. OTC
        • 5.2.1.2. Rx Drugs
      • 5.2.2. Global Genitourinary System Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
      • 5.2.3. Global Genitourinary System Treatment by: Drugs (Value)
        • 5.2.3.1. Hormonal Therapy
        • 5.2.3.2. Impotence Agents
        • 5.2.3.3. Uterine Relaxants
        • 5.2.3.4. Urinary Antispasmodics
        • 5.2.3.5. Urinary pH Modifiers
        • 5.2.3.6. Uterine Stimulants
        • 5.2.3.7. Miscellaneous Genitourinary Tract Agents
      • 5.2.4. Global Genitourinary System Treatment by: Disease Type (Value)
        • 5.2.4.1. Renal Failure
        • 5.2.4.2. Pyelonephritis
        • 5.2.4.3. Calculus of Kidney and Ureter
        • 5.2.4.4. Cystitis
        • 5.2.4.5. Cancer
        • 5.2.4.6. Infertility
        • 5.2.4.7. Endometriosis
        • 5.2.4.8. Others
      • 5.2.5. Global Genitourinary System Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Genitourinary System Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc. (United KIngdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Genitourinary System Treatment Sale, by Type, Application, Drugs, Disease Type and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Genitourinary System Treatment (Value)
      • 7.2.1. Global Genitourinary System Treatment by: Type (Value)
        • 7.2.1.1. OTC
        • 7.2.1.2. Rx Drugs
      • 7.2.2. Global Genitourinary System Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
      • 7.2.3. Global Genitourinary System Treatment by: Drugs (Value)
        • 7.2.3.1. Hormonal Therapy
        • 7.2.3.2. Impotence Agents
        • 7.2.3.3. Uterine Relaxants
        • 7.2.3.4. Urinary Antispasmodics
        • 7.2.3.5. Urinary pH Modifiers
        • 7.2.3.6. Uterine Stimulants
        • 7.2.3.7. Miscellaneous Genitourinary Tract Agents
      • 7.2.4. Global Genitourinary System Treatment by: Disease Type (Value)
        • 7.2.4.1. Renal Failure
        • 7.2.4.2. Pyelonephritis
        • 7.2.4.3. Calculus of Kidney and Ureter
        • 7.2.4.4. Cystitis
        • 7.2.4.5. Cancer
        • 7.2.4.6. Infertility
        • 7.2.4.7. Endometriosis
        • 7.2.4.8. Others
      • 7.2.5. Global Genitourinary System Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genitourinary System Treatment: by Type(USD Million)
  • Table 2. Genitourinary System Treatment OTC , by Region USD Million (2018-2023)
  • Table 3. Genitourinary System Treatment Rx Drugs , by Region USD Million (2018-2023)
  • Table 4. Genitourinary System Treatment: by Application(USD Million)
  • Table 5. Genitourinary System Treatment Hospital , by Region USD Million (2018-2023)
  • Table 6. Genitourinary System Treatment Clinics , by Region USD Million (2018-2023)
  • Table 7. Genitourinary System Treatment Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 8. Genitourinary System Treatment: by Drugs(USD Million)
  • Table 9. Genitourinary System Treatment Hormonal Therapy , by Region USD Million (2018-2023)
  • Table 10. Genitourinary System Treatment Impotence Agents , by Region USD Million (2018-2023)
  • Table 11. Genitourinary System Treatment Uterine Relaxants , by Region USD Million (2018-2023)
  • Table 12. Genitourinary System Treatment Urinary Antispasmodics , by Region USD Million (2018-2023)
  • Table 13. Genitourinary System Treatment Urinary pH Modifiers , by Region USD Million (2018-2023)
  • Table 14. Genitourinary System Treatment Uterine Stimulants , by Region USD Million (2018-2023)
  • Table 15. Genitourinary System Treatment Miscellaneous Genitourinary Tract Agents , by Region USD Million (2018-2023)
  • Table 16. Genitourinary System Treatment: by Disease Type(USD Million)
  • Table 17. Genitourinary System Treatment Renal Failure , by Region USD Million (2018-2023)
  • Table 18. Genitourinary System Treatment Pyelonephritis , by Region USD Million (2018-2023)
  • Table 19. Genitourinary System Treatment Calculus of Kidney and Ureter , by Region USD Million (2018-2023)
  • Table 20. Genitourinary System Treatment Cystitis , by Region USD Million (2018-2023)
  • Table 21. Genitourinary System Treatment Cancer , by Region USD Million (2018-2023)
  • Table 22. Genitourinary System Treatment Infertility , by Region USD Million (2018-2023)
  • Table 23. Genitourinary System Treatment Endometriosis , by Region USD Million (2018-2023)
  • Table 24. Genitourinary System Treatment Others , by Region USD Million (2018-2023)
  • Table 25. South America Genitourinary System Treatment, by Country USD Million (2018-2023)
  • Table 26. South America Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 27. South America Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 28. South America Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 29. South America Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 30. Brazil Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 31. Brazil Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 32. Brazil Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 33. Brazil Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 34. Argentina Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 35. Argentina Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 36. Argentina Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 37. Argentina Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 38. Rest of South America Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 41. Rest of South America Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 42. Asia Pacific Genitourinary System Treatment, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 44. Asia Pacific Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 45. Asia Pacific Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 46. Asia Pacific Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 47. China Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 48. China Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 49. China Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 50. China Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 51. Japan Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 52. Japan Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 53. Japan Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 54. Japan Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 55. India Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 56. India Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 57. India Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 58. India Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 59. South Korea Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 60. South Korea Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 61. South Korea Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 62. South Korea Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 63. Taiwan Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 64. Taiwan Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 65. Taiwan Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 66. Taiwan Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 67. Australia Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 68. Australia Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 69. Australia Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 70. Australia Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 75. Europe Genitourinary System Treatment, by Country USD Million (2018-2023)
  • Table 76. Europe Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 77. Europe Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 78. Europe Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 79. Europe Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 80. Germany Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 81. Germany Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 82. Germany Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 83. Germany Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 84. France Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 85. France Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 86. France Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 87. France Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 88. Italy Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 89. Italy Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 90. Italy Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 91. Italy Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 92. United Kingdom Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 93. United Kingdom Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 94. United Kingdom Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 95. United Kingdom Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 96. Netherlands Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 97. Netherlands Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 98. Netherlands Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 99. Netherlands Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 100. Rest of Europe Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 101. Rest of Europe Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 102. Rest of Europe Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 103. Rest of Europe Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 104. MEA Genitourinary System Treatment, by Country USD Million (2018-2023)
  • Table 105. MEA Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 106. MEA Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 107. MEA Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 108. MEA Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 109. Middle East Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 110. Middle East Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 111. Middle East Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 112. Middle East Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 113. Africa Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 114. Africa Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 115. Africa Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 116. Africa Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 117. North America Genitourinary System Treatment, by Country USD Million (2018-2023)
  • Table 118. North America Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 119. North America Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 120. North America Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 121. North America Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 122. United States Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 123. United States Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 124. United States Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 125. United States Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 126. Canada Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 127. Canada Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 128. Canada Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 129. Canada Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 130. Mexico Genitourinary System Treatment, by Type USD Million (2018-2023)
  • Table 131. Mexico Genitourinary System Treatment, by Application USD Million (2018-2023)
  • Table 132. Mexico Genitourinary System Treatment, by Drugs USD Million (2018-2023)
  • Table 133. Mexico Genitourinary System Treatment, by Disease Type USD Million (2018-2023)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Genitourinary System Treatment: by Type(USD Million)
  • Table 143. Genitourinary System Treatment OTC , by Region USD Million (2024-2029)
  • Table 144. Genitourinary System Treatment Rx Drugs , by Region USD Million (2024-2029)
  • Table 145. Genitourinary System Treatment: by Application(USD Million)
  • Table 146. Genitourinary System Treatment Hospital , by Region USD Million (2024-2029)
  • Table 147. Genitourinary System Treatment Clinics , by Region USD Million (2024-2029)
  • Table 148. Genitourinary System Treatment Ambulatory Surgical Centers , by Region USD Million (2024-2029)
  • Table 149. Genitourinary System Treatment: by Drugs(USD Million)
  • Table 150. Genitourinary System Treatment Hormonal Therapy , by Region USD Million (2024-2029)
  • Table 151. Genitourinary System Treatment Impotence Agents , by Region USD Million (2024-2029)
  • Table 152. Genitourinary System Treatment Uterine Relaxants , by Region USD Million (2024-2029)
  • Table 153. Genitourinary System Treatment Urinary Antispasmodics , by Region USD Million (2024-2029)
  • Table 154. Genitourinary System Treatment Urinary pH Modifiers , by Region USD Million (2024-2029)
  • Table 155. Genitourinary System Treatment Uterine Stimulants , by Region USD Million (2024-2029)
  • Table 156. Genitourinary System Treatment Miscellaneous Genitourinary Tract Agents , by Region USD Million (2024-2029)
  • Table 157. Genitourinary System Treatment: by Disease Type(USD Million)
  • Table 158. Genitourinary System Treatment Renal Failure , by Region USD Million (2024-2029)
  • Table 159. Genitourinary System Treatment Pyelonephritis , by Region USD Million (2024-2029)
  • Table 160. Genitourinary System Treatment Calculus of Kidney and Ureter , by Region USD Million (2024-2029)
  • Table 161. Genitourinary System Treatment Cystitis , by Region USD Million (2024-2029)
  • Table 162. Genitourinary System Treatment Cancer , by Region USD Million (2024-2029)
  • Table 163. Genitourinary System Treatment Infertility , by Region USD Million (2024-2029)
  • Table 164. Genitourinary System Treatment Endometriosis , by Region USD Million (2024-2029)
  • Table 165. Genitourinary System Treatment Others , by Region USD Million (2024-2029)
  • Table 166. South America Genitourinary System Treatment, by Country USD Million (2024-2029)
  • Table 167. South America Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 168. South America Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 169. South America Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 170. South America Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 171. Brazil Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 172. Brazil Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 173. Brazil Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 174. Brazil Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 175. Argentina Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 176. Argentina Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 177. Argentina Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 178. Argentina Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 179. Rest of South America Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 180. Rest of South America Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 181. Rest of South America Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 182. Rest of South America Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 183. Asia Pacific Genitourinary System Treatment, by Country USD Million (2024-2029)
  • Table 184. Asia Pacific Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 185. Asia Pacific Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 186. Asia Pacific Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 187. Asia Pacific Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 188. China Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 189. China Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 190. China Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 191. China Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 192. Japan Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 193. Japan Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 194. Japan Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 195. Japan Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 196. India Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 197. India Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 198. India Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 199. India Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 200. South Korea Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 201. South Korea Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 202. South Korea Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 203. South Korea Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 204. Taiwan Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 205. Taiwan Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 206. Taiwan Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 207. Taiwan Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 208. Australia Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 209. Australia Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 210. Australia Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 211. Australia Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 212. Rest of Asia-Pacific Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 213. Rest of Asia-Pacific Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 214. Rest of Asia-Pacific Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 215. Rest of Asia-Pacific Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 216. Europe Genitourinary System Treatment, by Country USD Million (2024-2029)
  • Table 217. Europe Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 218. Europe Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 219. Europe Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 220. Europe Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 221. Germany Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 222. Germany Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 223. Germany Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 224. Germany Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 225. France Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 226. France Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 227. France Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 228. France Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 229. Italy Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 230. Italy Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 231. Italy Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 232. Italy Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 233. United Kingdom Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 234. United Kingdom Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 235. United Kingdom Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 236. United Kingdom Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 237. Netherlands Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 238. Netherlands Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 239. Netherlands Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 240. Netherlands Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 241. Rest of Europe Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 242. Rest of Europe Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 243. Rest of Europe Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 244. Rest of Europe Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 245. MEA Genitourinary System Treatment, by Country USD Million (2024-2029)
  • Table 246. MEA Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 247. MEA Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 248. MEA Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 249. MEA Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 250. Middle East Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 251. Middle East Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 252. Middle East Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 253. Middle East Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 254. Africa Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 255. Africa Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 256. Africa Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 257. Africa Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 258. North America Genitourinary System Treatment, by Country USD Million (2024-2029)
  • Table 259. North America Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 260. North America Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 261. North America Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 262. North America Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 263. United States Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 264. United States Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 265. United States Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 266. United States Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 267. Canada Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 268. Canada Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 269. Canada Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 270. Canada Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 271. Mexico Genitourinary System Treatment, by Type USD Million (2024-2029)
  • Table 272. Mexico Genitourinary System Treatment, by Application USD Million (2024-2029)
  • Table 273. Mexico Genitourinary System Treatment, by Drugs USD Million (2024-2029)
  • Table 274. Mexico Genitourinary System Treatment, by Disease Type USD Million (2024-2029)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genitourinary System Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Genitourinary System Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Genitourinary System Treatment: by Drugs USD Million (2018-2023)
  • Figure 7. Global Genitourinary System Treatment: by Disease Type USD Million (2018-2023)
  • Figure 8. South America Genitourinary System Treatment Share (%), by Country
  • Figure 9. Asia Pacific Genitourinary System Treatment Share (%), by Country
  • Figure 10. Europe Genitourinary System Treatment Share (%), by Country
  • Figure 11. MEA Genitourinary System Treatment Share (%), by Country
  • Figure 12. North America Genitourinary System Treatment Share (%), by Country
  • Figure 13. Global Genitourinary System Treatment share by Players 2023 (%)
  • Figure 14. Global Genitourinary System Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Genitourinary System Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2023
  • Figure 19. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 21. GlaxoSmithKline plc. (United KIngdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline plc. (United KIngdom) Revenue: by Geography 2023
  • Figure 23. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 27. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 31. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 33. Global Genitourinary System Treatment: by Type USD Million (2024-2029)
  • Figure 34. Global Genitourinary System Treatment: by Application USD Million (2024-2029)
  • Figure 35. Global Genitourinary System Treatment: by Drugs USD Million (2024-2029)
  • Figure 36. Global Genitourinary System Treatment: by Disease Type USD Million (2024-2029)
  • Figure 37. South America Genitourinary System Treatment Share (%), by Country
  • Figure 38. Asia Pacific Genitourinary System Treatment Share (%), by Country
  • Figure 39. Europe Genitourinary System Treatment Share (%), by Country
  • Figure 40. MEA Genitourinary System Treatment Share (%), by Country
  • Figure 41. North America Genitourinary System Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Astellas Pharma Inc. (Japan)
  • GlaxoSmithKline plc. (United KIngdom)
  • Eli Lilly and Company (United States)
  • Bayer AG (Germany)
  • Merck KGaA (Germany)
  • Abbott Laboratories (United States)
  • Merck & Co. (United States)
Additional players considered in the study are as follows:
Agouron Pharmaceuticals Inc. (United States) , Bristol-Myers Squibb Co. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 226 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genitourinary System Treatment Quantitative research analysis
Global Genitourinary System Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc. (United KIngdom), Eli Lilly and Company (United States), Bayer AG (Germany), Merck KGaA (Germany), Abbott Laboratories (United States) and Merck & Co. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in the Healthcare Technology" is seen as one of major influencing trends for Genitourinary System Treatment Market during projected period 2023-2029.
The Genitourinary System Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Genitourinary System Treatment Report?

Have a Query? Click Here

Other Related Reports

Biliary Tumor Comprehensive Study by Type (Mecine, Surgery, Other), Application (Hospitals, Clinics, Other) Players and Region - Global Market Outlook to 2029
$ 3500
Neutropenia Treatment Comprehensive Study by Type (Granulocyte -colony-stimulating factor (G-CSF), Antibiotics, Antifungal drugs), Disease Type (Cyclic neutropenia, Kostmann’s syndrome, Chronic idiop...
$ 3750
Omnitrope Comprehensive Study by Type (Injection, Oral), Application (Hospital, Medical Center, Others), Medical Conditions (Hormone Deficiency, Chronic Kidney Disease, Idiopathic Short Stature, Noon...
$ 3450
Artificial Tendons and Ligaments Comprehensive Study by Application (Knee Injuries, Shoulder Injuries, Foot and Ankle Injuries, Others), Implant Type (Silastic-Rod Implant, Carbon-Fiber Implant, Marl...
$ 3750
Atherosclerosis Comprehensive Study by Treatment (Medication, Catheter-based Procedures (Balloon angioplasty, Atherectomy), Surgery (Endarterectomy, Arterioplasty, Bypass)), Distribution Channel (Hos...
$ 3450
Blood Coagulants Comprehensive Study by Type (Aprotinin, Tranexamic Acid (TXA), Epsilon-Aminocaproic acid, Aminomethylbenzoic acid, Other), Application (Hemophilia, Surgery (Post-Operative Care), Men...
$ 3750